TY - JOUR
T1 - Fluoroquinolones in the treatment of cystic fibrosis
AU - Høiby, N
AU - Pedersen, S S
AU - Jensen, T
AU - Valerius, N H
AU - Koch, C
PY - 1993
Y1 - 1993
N2 - Cystic fibrosis patients suffer from recurrent and chronic lung infections mainly caused by Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa. The fluoroquinolones, notably ciprofloxacin and ofloxacin, represent an important addition to the therapy of P. aeruginosa infections. They offer the possibility of effective oral treatment for early colonisation as well as chronic infections, even in children. They are associated with only few and mild adverse effects. Development of resistance represents an increasing problem.
AB - Cystic fibrosis patients suffer from recurrent and chronic lung infections mainly caused by Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa. The fluoroquinolones, notably ciprofloxacin and ofloxacin, represent an important addition to the therapy of P. aeruginosa infections. They offer the possibility of effective oral treatment for early colonisation as well as chronic infections, even in children. They are associated with only few and mild adverse effects. Development of resistance represents an increasing problem.
KW - Ciprofloxacin/therapeutic use
KW - Cystic Fibrosis/drug therapy
KW - Drug Therapy, Combination
KW - Humans
KW - Ofloxacin/therapeutic use
KW - Pseudomonas Infections/prevention & control
U2 - 10.2165/00003495-199300453-00017
DO - 10.2165/00003495-199300453-00017
M3 - Review
C2 - 7689459
SN - 0012-6667
VL - 45 Suppl 3
SP - 98
EP - 101
JO - Drugs
JF - Drugs
ER -